Fig. 6From: Dual activity of PD-L1 targeted Doxorubicin immunoliposomes promoted an enhanced efficacy of the antitumor immune response in melanoma murine modelSystemic immune response was measured in spleen and lymph nodes collected from B16OVA tumor bearing mice treated with saline, free Dox, Conventional Dox liposomes (LPD), LPD co-administered with 28 µg of free α-PD-L1 (mAb) or Targeted Dox liposome or immunoliposomes (LPF). Dox was intravenously injected at 3 mg/kg and eight days later, organs were removed to analyze different T cell subpopulations. a Lymphocyte activation status determination in spleen after incubation with SIINFEKL peptides (ELISPOT); b Degree of activation (Granzyme B) measured in CD8+ cells in lymph nodes after 4 h of stimulation with PMA/Ionomicin. Bars show the maximum and minimum range of data with the mean. Data belong to two independent studies involving eight mice. **p < 0.01 compared to controlBack to article page